The Innovative Medicines Initiative (IMI) was set up in 2008 as a public-private partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceu-tical Industries and Associations).
At IMI, our goal is to improve the medicines development process and make it more ecient, and to ensure that patients will have faster access to better and safer medicines. We do this by funding collaborative projects that bring together all key groups involved in life science research. Through our projects, we are nding innovative solutions to the most pressing medical burdens of our time, including antimicrobial resistance, dementia, and diabetes.
Over a decade in, we are globally recognised as a pioneer of open innovation and an attractive model for successful public-private partnerships (PPPs) in research.
Interested? Find out more. >> 2020=booklet IMI